CD274 and cancer: Immunoinhibitors, such as PD-1, PD-L1, and CTLA-4, have gained widespread attention, as they can serve as immune checkpoint targets in multiple cancers to block immunoinhibitory signals and enable to produce effective antitumor responses (35).